Hemostasis and thrombosis are believed to be so intricately linked that any strategies that
reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is …

Despite advances in anticoagulant therapy, thrombosis remains the leading cause of
morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first …

Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically
improved the prevention of thrombosis. However, several unmet needs prevail in the field of …

The dose-limiting issue with available anticoagulant therapies is bleeding. Is there an
approach that could provide antithrombotic protection with reduced bleeding? One …

Background Phase II randomized controlled trials (RCTs) on factor (F) XI inhibitors have
shown promising results but they were burdened by low statistical power for clinical …

Coagulation factor (F) XI has been described as a component of the early phase of the
contact pathway of blood coagulation, acting downstream of factor XII. However, patients …

Abstract Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in
anticoagulation because it is involved primarily in thrombus formation and plays a much …

Although the non-vitamin antagonist oral anticoagulants produce less intracranial bleeding
than warfarin, serious bleeding still occurs. Therefore, the search for safer anticoagulants …